menu
    • menu

    Company profile for eGenesis

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. We are driven to provide hope to thousands of patients with end-stage organ disease by providing an alternative source of safe and effective human-compatible organs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    eGenesisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Technology Square Suite 301 Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://egenesisbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/egenesisbio/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/egenesisbio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    eGenesis Gets IND Clear for EGEN-2784 in Kidney Transplant Study
    eGenesis Gets IND Clear for EGEN-2784 in Kidney Transplant Study

    08 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-08/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in

    PHARMAWEB
    08 Sep 2025
    Share Share
    eGenesis Appoints Douglas Williams & Adam Craig to Board
    eGenesis Appoints Douglas Williams & Adam Craig to Board

    19 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250819727122/en/eGenesis-Appoints-Douglas-Williams-Ph.D.-and-Adam-Craig-M.D.-Ph.D.-to-its-Board-of-Directors

    BUSINESSWIRE
    19 Aug 2025
    Share Share
    eGenesis Appoints Dr. Jay Barth as Chief Medical Officer
    eGenesis Appoints Dr. Jay Barth as Chief Medical Officer

    06 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250506874422/en/eGenesis-Appoints-Dr.-Jay-Barth-as-Chief-Medical-Officer

    BUSINESSWIRE
    06 May 2025
    Share Share
    eGenesis & OrganOx get FDA clearance for liver failure Treatment
    eGenesis & OrganOx get FDA clearance for liver failure Treatment

    15 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250415526464/en/eGenesis-and-OrganOx-Announce-U.S.-FDA-Clearance-of-IND-Application-for-the-Treatment-of-Patients-with-Acute-On-Chronic-Liver-Failure

    BUSINESSWIRE
    15 Apr 2025
    Share Share
    OrganOx & eGenesis Announce Liver Failure Co-Development Deal
    OrganOx & eGenesis Announce Liver Failure Co-Development Deal

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2979032/0/en/OrganOx-and-eGenesis-Announce-Exclusive-Clinical-Co-Development-Agreement-for-Treatment-of-Patients-with-Liver-Failure-in-the-Acute-Setting.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share
    Natco Pharma acquires 40 million shares in eGenesis Inc
    Natco Pharma acquires 40 million shares in eGenesis Inc

    04 Sep 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-acquires-40-million-shares-in-egenesis-inc/articleshow/113059231.cms

    ECONOMICTIMES
    04 Sep 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search